KR101974501B1 - Method for preparing solid phase fermented acanthopanax extract by cordyceps as an active ingredient - Google Patents

Abstract

(A) preparing a sterilized oacus by sterilizing the washed oacus; (b) solid phase fermentation by inoculating the sterilized organisms with the mycelium of the organisms to produce solid phase fermented organisms; And (c) extracting the solid-phase fermented oacus with hot water or alcohol to prepare an oaci extract. The pharmaceutical composition according to the present invention comprises a solid fermented oaci extract as an active ingredient. Thus, it is possible to increase the contents of cordycepin and beta-glucan to enhance the effects of immunity enhancement, antioxidant, anti-fatigue, endocrine control, blood pressure control, anti-radioactivity and detoxification.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a method for producing a composition comprising an extract of Ogaki fermented in a solid state with Cordyceps sinensis as an active ingredient,

The present invention relates to a method for producing a composition comprising an extract of Ogaki as an active ingredient and a composition prepared by the method, and more particularly to a method for preparing a composition comprising an Ogaki extract obtained by solid- ≪ / RTI > to a composition prepared according to the method.

Acanthopanax sessiliflorum Seeman (Acanthopanax sessiliflorum Seeman) refers to the root of the root, stem and branches of the plant. The leaves are divided into five, and it is good to have five leaves on one branch, so it was called Oga and now it is described as Oga. This medicine has a peculiar smell, and the taste is spicy and the quality is warm. Ogapi is used to strengthen the tendons and bones by showing the energy of the liver and kidneys. It is used for limb paralysis, burning, softness symptoms of the waist and knee, weakness, numbness, fractures, bruises and edema. The pharmacological actions were immune enhancement, antioxidant, anti-fatigue, anti-hypertension, anti-irritation, endocrine control, blood pressure control, anti-radioactivity and detoxification.

On the other hand, the vegetable worms are a mysterious mushroom that blooms in the body of the insect larvae or adults during the winter season, while the mycelium of the mushrooms lie in the bodies of insects.

The Cordyceps is a mushroom that grows in the highlands of 4,000 m above sea level in China's Qinghai, Sekwang, and Yunnan provinces. It is said to be very valuable and has been called a mysterious mushroom that exceeds ginseng and antler. The kinds of Chinese caterpillar fungus include Cryptomeria japonica, Cordyceps caterpillar, Cordyceps caterpillar, Chrysalis caterpillars, Snowflake caterpillars, Corynebacterium caterpillars, and Beet caterpillars.

In 1997, it succeeded in artificial cultivation of caterpillar fungus in Korea and it became possible to mass-produce it. In the case of Cordyceps, Cordyceps sinensis ), japonica ( Paecilomyces japonica , and Cordyceps militaris . Depending on which insects they have grown up, they will have a variety of shapes and shapes.

Thus, there is a need to develop a new substance that maximizes the beneficial ingredient content of the ginseng, which is beneficial to the human body, using the ginseng extract, or that is converted into a form in which the beneficial ingredient is easily absorbed by the human body.

Korean Patent Registration No. 10-399374 Korean Patent Publication No. 2003-86749

It is an object of the present invention to provide a method for fermenting ogpei by solid-phase fermentation using Cordyceps sinensis to ferment lignin glycosides, eleutheroside B and eleutheroside E, (Cordycepin) which is a physiologically active ingredient and an insecticidal extract which is capable of increasing beta-glucan content and which is solid-phase fermented by fermentation, as an active ingredient, .

Another object of the present invention is to provide a pharmaceutical or food composition containing an extract of Ogaki as an active ingredient in accordance with the above method to produce health functionalities such as immunity enhancement, antioxidant, anti-fatigue, endocrine control, blood pressure control, anti- Or a pharmaceutically acceptable salt thereof.

According to an aspect of the present invention,

 (a) sterilizing the washed oacus to prepare a sterilized oacus; (b) solid phase fermentation by inoculating the sterilized organisms with the mycelium of the organisms to produce solid phase fermented organisms; And (c) extracting the solid-phase fermented oacus with hot water or alcohol to produce an oacassi extract. The method of producing a pharmaceutical composition comprising the solid oacum extract as an active ingredient is provided.

Preferably, the sterilized organs may have a water content of 5 to 20 wt%.

In step (a), the sterilization may be carried out for 20 to 50 minutes under a high temperature and high pressure of 110 to 140 캜, 1.0 to 1.2 kg / cm 2.

After step (a), the sterilized oacus can be cooled at a rate of 5 to 10 ° C / min.

In step (b), the fungus mycelium is coordinated sepseu sinen sheath (Cordyceps sinensis), coordination sepseu Millar other less (Cordyceps militaris , Cordyceps < RTI ID = 0.0 > scarabaecola , Cordyceps nutans , Cordyceps < RTI ID = 0.0 > sphecocephala , Cordyceps tricentri , Paecilomyceps tenuipes , and Paecilomyces japonica .

In step (b), 1 to 3 parts by weight of a saccharide may be added to 100 parts by weight of the sterilized oyster.

In step (b), said solid phase fermentation can be carried out at 20 to 25 DEG C for 10 to 30 days.

According to another aspect of the present invention,

There is provided a pharmaceutical composition comprising the solid-phase fermented oak extract prepared according to the above method as an active ingredient.

According to another aspect of the present invention,

(a) sterilizing the washed oacus to prepare a sterilized oacus; (b) solid phase fermentation by inoculating the sterilized organisms with the mycelium of the organisms to produce solid phase fermented organisms; And (c) extracting the solid-phase fermented oacus with hot water or alcohol to produce an oacassi extract. The present invention also provides a method for producing a food composition comprising the solid oacetabi extract as an active ingredient.

According to another aspect of the present invention,

There is provided a food composition comprising as an active ingredient a solid fermented oak extract prepared according to the above method.

The method for producing a pharmaceutical or food composition containing the extract of Ogaki fermented in solid phase with Cordyceps sinensis according to the present invention comprises the steps of solid-phase fermentation of Oggia with Cordyceps sinensis to produce a lignin glycoside, Eureteoside B and feruteroside E (eleutheroside E) can be fermented to convert into a fermentation product that can be easily absorbed into the human body, and the content of physiologically active Cordycepin and beta-glucan can be increased.

The pharmaceutical or food composition comprising the extract of Ogaki fermented by solid phase fermented with Cordycepsae according to the present invention as an active ingredient can be used as a pharmaceutical or food having health function such as immunity enhancement, antioxidant, anti-fatigue, endocrine control, blood pressure control, anti- Compositions.

Fig. 1 shows HPLC chromatogram results according to Test Example 1. Fig.

BRIEF DESCRIPTION OF THE DRAWINGS The present invention is capable of various modifications and various embodiments, and specific embodiments are illustrated in the drawings and described in detail in the detailed description. It is to be understood, however, that the invention is not to be limited to the specific embodiments, but includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.

Hereinafter, a method for producing a pharmaceutical composition comprising the solid-phase fermented ocher extract of the present invention as an active ingredient will be described.

First, the washed organisms are sterilized to prepare sterilized organisms (step a).

The sterilization is preferably performed at a high temperature and a high pressure of 110 to 140 ° C and 1.0 to 1.2 kg / cm 2 for 20 to 50 minutes. If the temperature, pressure, and time are less than the lower limit value, sterilization may not be performed. If the temperature, pressure, and time are higher than the upper limit value, the component of the ophthalmia may be denatured.

Preferably, the sterilized ophthalmic composition has a water content of 5 to 20 wt%. When the moisture content is too low, the fermentation may not occur properly. If the moisture content is too high, the fermentation may be inhibited.

After step (a), it is preferable to cool the sterilized oacus to room temperature at a rate of 5 to 10 ° C / min. If the cooling rate is lower than the lower limit, it takes a long time to cool down to room temperature. If the cooling rate is higher than the upper limit, the desired component can not be increased.

Next, the above-mentioned sterilized organs were inoculated with the mycelia of Cordyceps, Solid fermentation  By Solid fermented  (Step b).

The inoculation of the above-mentioned organisms may be carried out by inoculating the surface of the plant.

The above-mentioned mycelia of Cordyceps mellifera were Cordyceps spp . ) Can be used, and preferably, Cordyceps sinensis , Cordyceps militaris , Cordyceps < RTI ID = 0.0 > scarabaecola , Cordyceps nutans , Cordyceps sphecocephala , Cordyceps tricentri , Paecilomyceps tenuipes , Paecilomyces < RTI ID = 0.0 > japonica ) and the like.

In some cases, 1 to 3 parts by weight of a saccharide may be added to 100 parts by weight of the sterilized oyster to perform solid phase fermentation.

The solid phase fermentation is preferably performed at 20 to 25 DEG C for 10 to 30 days. When the solid phase fermentation temperature and time are less than the lower limit value, the efficiency of fermentation may be lowered, and when the upper limit value is exceeded, some of the organoleptic components may be denatured.

Finally, Solid fermented  Ogapi Heat number  Or extracting into a syrup to prepare an acai extract (step c).

The extraction solvent used in the present invention includes water, a lower alcohol having 1 to 4 carbon atoms, a mixed solvent of the lower alcohol and water, acetone, ethyl acetate, chloroform, butyl acetate, 1,3-butylene glycol, Ether, and the like. More preferably, water or ethanol is used.

As used herein, the term 'extract' has the meaning of being used as a crude extract in the art, but broadly it can also include fractions in which the extract is further fractionated. It can also be prepared in powder form by further processes such as vacuum distillation and lyophilization or spray drying.

As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve the efficacy or activity of the plant. In one embodiment of the invention, in the composition of the present invention, the ogap is, for example, at least 0.001 mg / kg, preferably at least 0.1 mg / kg, more preferably at least 10 mg / kg, More preferably 100 mg / kg or more, still more preferably 250 mg / kg or more, and most preferably 0.1 g / kg or more. As the natural product, there is no adverse effect on the human body even when the natural product is administered in an excessive amount, so that the quantitative upper limit of the amount of the active ingredient contained in the composition of the present invention can be selected by a person skilled in the art within a suitable range.

The pharmaceutical composition of the present invention may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Or a flavoring agent may be used.

The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.

The pharmaceutical form of the pharmaceutical composition may be a granule, a powder, a tablet, a coated tablet, a capsule, a suppository, a liquid, a syrup, a juice, a suspension, an emulsion, a drip agent or an injectable liquid agent. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, And other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added as needed. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.

The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration.

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate and responsiveness of the patient, , A skilled physician can readily determine and prescribe dosages that are effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.

The pharmaceutical composition of the present invention may be prepared in a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs Into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

In addition, the present invention provides a food composition comprising a solid-phase fermented acacia extract as an active ingredient.

The description of the solid-phase fermented ocher extract is the same as that described in the above-mentioned pharmaceutical composition, and therefore, the above-mentioned contents will be referred to for the details.

The food composition according to the present invention can be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meats, chocolates, pizza, breads, ramen noodles, gums, ice cream, And supplementary foods.

The food composition of the present invention may contain, as an active ingredient, not only an acanthoma extract, but also components that are ordinarily added in the course of food production, including, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavors. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared from a drink and a beverage, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, various plant extracts and the like may be further included in addition to the extract of the present invention.

The present invention provides a health functional food comprising a food composition comprising an extract of Ogaki as an active ingredient. A health functional food is a food prepared by adding an extract of Ogaki to a food material such as a beverage, a tea, a spice, a gum, or a confection, or encapsulated, powdered, or a suspension, and has a health-specific effect Meaning, unlike general medicine, there is an advantage that there is no side effect that can occur when a food is used as a raw material for a long time. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The amount of the extract of Ogaki extract in such a health functional food can not be uniformly determined depending on the kind of the health functional food to which it is added but may be added within a range that does not impair the original taste of the food, To 50% by weight, preferably 0.1 to 20% by weight. In the case of health functional foods in the form of pills, granules, tablets or capsules, they may be added usually in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.

[Example]

Example  One

After washing 100 g of the dried ogapi, moisture was added to make the moisture content about 15 wt%. The water-added O-phial was sterilized at 121 DEG C for 25 minutes at a high temperature and a high pressure and then cooled to 25 DEG C at a rate of 7 DEG C / min. Cordyceps militaris was inoculated on the surface of the O- %, And solid phase fermentation was carried out. The solid phase fermentation was carried out for 15 days at 22 ° C and a relative humidity of 50%. After completion of the solid phase fermentation, hot water extraction was performed to obtain a solid fermented ocher extract.

Comparative Example  One

The dried oranges used in Example 1 were subjected to solid-phase fermentation to prepare an acacia extract.

[Test Example]

Test Example  1: Analysis of acetic acid glycoside components

The main components of the ginger are lignin glycoside eleutheroside B, eleutheoside E, caffeic acid, friedelin, phenolic glycoside, β-sitosterol, isofraxidin, β-glucan, Among the eleutherosides B and E, 80% of the components of the plant glycoside are different. The analysis of eleutheroside B and eleutheroside E was carried out in the following manner.

Eleutheosides B and E were analyzed using a Variable Wavelength Detector (210 nm, Dionex, Waltham, Mass., USA) and a Triart C18 column (5.0 μm, 4.6 mm × 150 mm; 25 ° C.). The mobile phase was water (0.1% TFA) and acetonitrile (0.1% TFA). The flow rate was 1.0 mL / min and the injection volume was 20 μl. The gradient conditions for the mobile phase were acetonitrile (0.1% TFA) at 15 to 15%, 15 to 20 minutes at 20 to 25 minutes, 15 to 20 minutes at 20 to 25 minutes 15%. Eleutheoside B was dissolved in sterilized water and quantitated using a calibration formula y = 341.62x + 2.6085 (R2 = 0.9978) in the range of 0.003-0.420 mM. Eureteoside E was dissolved in sterilized water to give 0.002-0.210 mM (Y = 1265.9x + 4.8299 (R2 = 0.9997)). The content of the useful ingredient is represented by the elution relative to the solids content (g) used in the elution, extraction, and the amount (mg) of the extracted ingredient.

Eureteoside B and E contents of the Ogaki extract used as a raw material and the Ogaki extract obtained by solid-phase fermentation for 15 days are shown in Table 1 below and the results of HPLC chromatogram are shown in Fig.

division Content (mg / g) Eleutheroside B Eleutheroside E Example 1 0.485 + 0.015 0.455 + 0.035 Comparative Example 1 0.556 + 0.024 0.874 + 0.071

According to Table 1, each component decreased after the solid phase fermentation, which is considered to be due to the decomposition of the sugar component of the lignan glycosides during the fermentation process and conversion into fermentation products. Further, according to Fig. 1, a new peak was shown in the results of Example 1, which means that the metabolic component can be more easily absorbed by the human body than the lignan glycoside component present in the raw material of Comparative Example 1.

Test Example  2: Godisepin  beta- Glucan  Content analysis

The results of measurement of the content of cordisepine and beta-glucan in the extract of Ogaki prepared according to Example 1 and Comparative Example 1 are shown in Tables 2 and 3, respectively. The content of cordycepin was measured by filtration of the Ogaki extract, concentration in vacuum and freeze-dried powder.

division Codispein content (mg / Kg) Example 1 15.485 ± 0.955 Comparative Example 1 0

division Beta Glucan Content (mg / g) Example 1 32.64 + - 2.34 Comparative Example 1 24.15 ± 1.56

According to Tables 2 and 3, cordycepin, which was not included in the raw materials for the raw materials, was produced after solid phase fermentation, and beta glucan was found to increase by about 8 mg / g by solid phase fermentation.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, many modifications and changes may be made by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims. The present invention can be variously modified and changed by those skilled in the art, and it is also within the scope of the present invention.

Claims (10)

(a) sterilizing the washed oyster for 20 to 50 minutes at a high temperature and a high pressure of 110 to 140 캜, 1.0 to 1.2 kg / cm 2 to prepare a sterilized oacus;
(b) solid phase fermentation by inoculating the sterilized organisms with the mycelium of the organisms to produce solid phase fermented organisms; And
(c) extracting the solid-phase fermented oacus with hot water or alcohol to prepare an oaci extract,
The sterilized ophthalmia of step (a) has a water content of 15 to 20 wt%
After step (a), the sterile ophthalmic solution is cooled at a rate of 5 to 10 DEG C / min,
Wherein, in step (b), 1 to 3 parts by weight of a saccharide is added to 100 parts by weight of the sterilized oyster, and the solid-phase fermentation is performed at 20 to 25 ° C for 10 to 30 days ,
Wherein the food composition contains an extract of Ogaki which has a higher content of codisepin and beta glucan and is fermented in solid phase as an active ingredient. delete delete delete The method according to claim 1,
In step (b), the mycelia of Cordyceps sinensis are selected from the group consisting of Cordyceps sinensis, Cordyceps militaris, Cordyceps scarabaecola, Cordyceps nutans, Wherein said at least one selected from the group consisting of Cordyceps sphecocephala, Cordyceps tricentri, Paecilomyceps tenuipes and Paecilomyces japonica. A method for producing a food composition comprising an extract of Ogaki as an active ingredient. delete delete delete delete delete

Images